Pierre Fabre Group
This executive role leads the Value and Access team at Pierre Fabre Pharmaceuticals, focusing on securing reimbursement and pricing strategies for innovative cell therapies and rare disease treatments. The incumbent will drive the successful launch of tabelecleucel while managing payer relationships, health economics initiatives, and distribution policies to maximize therapeutic access. This position requires deep expertise in the US healthcare system and collaboration with global partners to optimize commercial success for complex patients.
Founded in 1962 by Mr. Pierre Fabre, Pierre Fabre is an international French pharmaceutical and dermo-cosmetic group owned by a public benefit foundation and its employees.
Naos appoints Frédéric Ennabli, former Pierre Fabre executive, as board chairman
Sep 29, 2025
Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche markets
Oct 10, 2022
Pierre Fabre Has Acquired Dermocosmetics Brand Même
May 9, 2023
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Pierre Fabre Group.
103% above the average for this role
Eric Ducournau Named Chief Executive Officer of the Pierre Fabre Group
May 31, 2018
Manager-Value & Access
Eli Lilly and Company
National Access Director
Pierre Fabre
Senior Director, US Market Access
Mirum Pharmaceuticals
Senior Manager, Value and Access Solutions
Cardinal Health
Executive Director, Cell & Gene Therapy Value & Access Lead (Neuro & Rare)
Insmed Incorporated
Health Economics & Payer Evidence Lead
AstraZeneca